The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome

A pilot randomized trial of pentoxifylline for the reduction of periprocedural myocardial injury in patients undergoing elective percutaneous coronary intervention

“…Concerning the changes of cardiac biomarkers in the control groups, the changes of troponins in the Piot et al [24] (pretreatment cyclosporine), Froughinia et al [23] (pretreatment omega-3), and Yun et al [19] (loading of rosuvastatin) studies were not significant that is in agreement with our study. However, in these studies, CK-MB significantly increased in their control groups when compared with their intervention groups.…”

“…Several mechanisms are involved in the development of this type, which include the distal embolisms of atheromatous plaque and thrombotic components during angioplasty, platelet activation and thrombosis formation as a result of the activation of coagulation factors, neurohormonal activation and coronary vasospasm, the oxidative stress which is identified by elevation of some biomarkers such as isoprostane-PG(F2) Alfa and ischemia-modified albumin, and finally, inflammation which is recognized by raising of inflammatory biomarkers such as IL-6 and CRP during angioplasty [7]. Given the mechanistic basis of PMI, a large number of studies have investigated the potential benefits of some medications as a cardioprotective agent in the prevention of PMI [15][16][17][18][19][20][21][22][23][24].…”

“…Accordingly, the positive role of statins in the reduction of PMI in the setting of urgent PCI has been elucidated by ARMYDA-ACS (loading of atorvastatin), ARMYDA-RECAPTURE (reloading of atorvastatin before PCI), and Yun et al (loading of rosuvastatin) trials [17][18][19]. The potential benefit of pretreatment statin in the prevention of PMI has been also illustrated in Merla et al meta-analysis including nine trials with 4751 patients.…”

Early Statin Therapy Within 48 Hours Decreased One-Year Major Adverse Cardiac Events in Patients With Acute Myocardial Infarction

“…[14][15][16] In patients with ACS, especially those undergoing PCI, early statin therapy has resulted in lower cardiovascular mortality and better angiographic profiles. [17][18][19] The efficacy of statins has been demonstrated in many clinical studies in AMI patients as well as in ACS patients. In our study, there were more patients with STEMI than non-STEMI in the early statin group.…”

Estudo randomizado da intervenção coronária percutânea após administração da rosuvastatina para prevenção de infarto do miocárdio periprocedimento

“…Embora este procedimento seja seguro e com baixos índices de complicações, a elevação de biomarcadores cardíacos ocorre em 5% a 40% dos pacientes, a depender do biomarcador cardíaco utilizado, das abordagens antitrombóticas, do perfil clínico e angiográfico do paciente [1][2][3][4] . [28][29][30][31][32][33][34][35][36][37][38][39][40] Como ainda não existe estudo sobre a realização da ICP na hora do pico de concentração da estatina, permanecem dúvidas sobre definição de temporalidade adequada para sua administração (de horas até semanas), a dose ideal e o tipo de estatina.…”